# An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

> **NCT00417118** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 365 (actual)

## Conditions studied

- Generalized Anxiety

## Interventions

- **DRUG:** Saredutant
- **DRUG:** Escitalopram
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00417118
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2016-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00417118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00417118, "An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00417118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*